|
1
|
Shah P, Kerns E, Nguyen DT, Obach RS, Wang AQ, Zakharov A, McKew J, Simeonov A, Hop CECA, Xu X. An Automated High-Throughput Metabolic Stability Assay Using an Integrated High-Resolution Accurate Mass Method and Automated Data Analysis Software. ACTA ACUST UNITED AC 2016; 44:1653-61. [PMID: 27417180 DOI: 10.1124/dmd.116.072017] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2016] [Accepted: 07/13/2016] [Indexed: 01/08/2023]
Abstract
Advancement of in silico tools would be enabled by the availability of data for metabolic reaction rates and intrinsic clearance (CLint) of a diverse compound structure data set by specific metabolic enzymes. Our goal is to measure CLint for a large set of compounds with each major human cytochrome P450 (P450) isozyme. To achieve our goal, it is of utmost importance to develop an automated, robust, sensitive, high-throughput metabolic stability assay that can efficiently handle a large volume of compound sets. The substrate depletion method [in vitro half-life (t1/2) method] was chosen to determine CLint The assay (384-well format) consisted of three parts: 1) a robotic system for incubation and sample cleanup; 2) two different integrated, ultraperformance liquid chromatography/mass spectrometry (UPLC/MS) platforms to determine the percent remaining of parent compound, and 3) an automated data analysis system. The CYP3A4 assay was evaluated using two long t1/2 compounds, carbamazepine and antipyrine (t1/2 > 30 minutes); one moderate t1/2 compound, ketoconazole (10 < t1/2 < 30 minutes); and two short t1/2 compounds, loperamide and buspirone (t½ < 10 minutes). Interday and intraday precision and accuracy of the assay were within acceptable range (∼12%) for the linear range observed. Using this assay, CYP3A4 CLint and t1/2 values for more than 3000 compounds were measured. This high-throughput, automated, and robust assay allows for rapid metabolic stability screening of large compound sets and enables advanced computational modeling for individual human P450 isozymes.
Collapse
Affiliation(s)
- Pranav Shah
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville Maryland (P.S, E.K, D-T.N, A Q.W, A.Z, J.M, A.S, X.X.); Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer. Groton, Connecticut (R.S.O.); and Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (C.E.C.A.H)
| | - Edward Kerns
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville Maryland (P.S, E.K, D-T.N, A Q.W, A.Z, J.M, A.S, X.X.); Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer. Groton, Connecticut (R.S.O.); and Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (C.E.C.A.H)
| | - Dac-Trung Nguyen
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville Maryland (P.S, E.K, D-T.N, A Q.W, A.Z, J.M, A.S, X.X.); Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer. Groton, Connecticut (R.S.O.); and Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (C.E.C.A.H)
| | - R Scott Obach
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville Maryland (P.S, E.K, D-T.N, A Q.W, A.Z, J.M, A.S, X.X.); Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer. Groton, Connecticut (R.S.O.); and Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (C.E.C.A.H)
| | - Amy Q Wang
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville Maryland (P.S, E.K, D-T.N, A Q.W, A.Z, J.M, A.S, X.X.); Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer. Groton, Connecticut (R.S.O.); and Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (C.E.C.A.H)
| | - Alexey Zakharov
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville Maryland (P.S, E.K, D-T.N, A Q.W, A.Z, J.M, A.S, X.X.); Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer. Groton, Connecticut (R.S.O.); and Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (C.E.C.A.H)
| | - John McKew
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville Maryland (P.S, E.K, D-T.N, A Q.W, A.Z, J.M, A.S, X.X.); Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer. Groton, Connecticut (R.S.O.); and Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (C.E.C.A.H)
| | - Anton Simeonov
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville Maryland (P.S, E.K, D-T.N, A Q.W, A.Z, J.M, A.S, X.X.); Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer. Groton, Connecticut (R.S.O.); and Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (C.E.C.A.H)
| | - Cornelis E C A Hop
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville Maryland (P.S, E.K, D-T.N, A Q.W, A.Z, J.M, A.S, X.X.); Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer. Groton, Connecticut (R.S.O.); and Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (C.E.C.A.H)
| | - Xin Xu
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Rockville Maryland (P.S, E.K, D-T.N, A Q.W, A.Z, J.M, A.S, X.X.); Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer. Groton, Connecticut (R.S.O.); and Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (C.E.C.A.H)
| |
Collapse
|